<DOC>
	<DOC>NCT01855087</DOC>
	<brief_summary>There is paucity of information about the combination therapy with dipeptidyl peptidase-4 inhibitor sitagliptin and insulin. This study aimed to retrospectively investigate the safety and efficacy of this therapeutic modality in Japanese patients with type 2 diabetes.</brief_summary>
	<brief_title>Safety and Efficacy of Sitagliptin Added to Insulin Therapy for Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>outpatients with type 2 diabetes addition of sitagliptin to insulin therapy aged 20 years or older HbA1c of 6.9% or higher (NGSP) at the time of adding sitagliptin history of hypersensitivity to sitagliptin severe ketosis, diabetic coma, and/or precoma within 6 months before sitagliptin administration sever infection and/or severe trauma, and/or patients who are scheduled to undergo / have recently underwent surgery severe renal dysfunction (serum creatinine [mg/dL]: 2.5 or higher for men; 2.0 or higher for women) ongoing treatment with glinide(s) judgment as ineligible for the study by the attending physician</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>